Repligen Corporation's SEC filings document financial reporting, governance and public-company capital structure for a Nasdaq-listed life sciences company in bioprocessing technology. Recent Form 8-K reports attach earnings releases for quarterly and annual results, financial guidance and non-GAAP measures such as organic revenue, adjusted operating income, adjusted EPS and adjusted EBITDA.
The filing record also includes definitive proxy materials covering board matters, executive compensation and equity awards, along with Form 8-K disclosures on officer appointments, principal accounting officer responsibilities, financial reporting oversight and Sarbanes-Oxley-related infrastructure. Securities registration disclosures identify RGEN common stock, par value $0.01 per share, on the Nasdaq Global Select Market.
Repligen Corporation’s CFO Jason K. Garland reported routine tax-related share withholdings. On March 2, 2026, the company withheld 715 shares of common stock at $124.97 per share, and on February 27, 2026, it withheld 327 shares at $128.73 per share to satisfy tax obligations triggered by restricted stock unit releases. These dispositions were for tax withholding rather than open-market sales.
Repligen Corp senior vice president of R&D Ralf Kuriyel reported two tax-related share dispositions. On February 27, 2026, the company withheld 444 shares of common stock at $128.73 to cover tax obligations from restricted stock units vesting.
On March 2, 2026, the company similarly withheld 923 shares at $124.97. After the later transaction, Kuriyel directly owned 14,695 common shares. These were tax-withholding events rather than open-market sales.
Repligen Corp chief product officer Brian Robb reported a small share disposition tied to taxes rather than an open-market trade. On the reported date, 221 shares of common stock were withheld by the company at $124.97 per share to cover tax obligations arising from the release of restricted stock units. After this tax-withholding transaction, Robb’s directly held common stock balance was 8,319 shares.
Repligen Corporation provides an annual overview of its global bioprocessing business, describing franchises in filtration, chromatography, process analytics and proteins that serve biologics and emerging gene and cell therapy markets. The company estimates a roughly $13 billion addressable market within a $20 billion global bioprocessing space.
Repligen highlights growth via innovation, integrated solutions and targeted acquisitions, including the 2025 purchase of 908 Devices’ bioprocess PAT portfolio, while operating 19 manufacturing sites and employing about 2,000 people worldwide. The filing also outlines key risks, such as customer and supplier concentration, competition, foreign exchange exposure, $600 million of 1.00% convertible notes due 2028 and material weaknesses in internal controls.
Repligen Corporation reported strong fourth-quarter and full-year 2025 results and issued upbeat 2026 guidance. Q4 2025 revenue reached $198 million, up 18% year over year (14% organic). Full-year 2025 revenue was $738 million, a 16% increase with 14% organic growth.
Profitability improved sharply. Full-year GAAP income from operations was $55 million versus a loss of $35 million in 2024, while GAAP net income was $48.9 million compared to a $25.5 million loss. Adjusted net income rose to $96.9 million, with adjusted diluted EPS of $1.71 versus $1.58.
Margins expanded, with 2025 GAAP gross margin at 52.3% and adjusted operating margin at 13.8%. For 2026, Repligen guides revenue of $810–$840 million (10–14% reported growth, 9–13% organic), adjusted operating margin of 15.1–15.5%, adjusted EBITDA margin of 20–20.5%, and diluted EPS of $1.93–$2.01. Cash, cash equivalents and marketable securities totaled $768 million at December 31, 2025.
T. Rowe Price Associates, Inc. filed an amended Schedule 13G reporting a significant ownership position in Repligen Corp. common stock. The firm reports beneficial ownership of 4,599,860 shares, representing 8.2% of the outstanding common stock as of December 31, 2025.
T. Rowe Price states it has sole voting power over 4,301,925 shares and sole dispositive power over 4,599,061 shares, with no shared voting or dispositive power. It certifies the shares were acquired and are held in the ordinary course of business and not for the purpose of influencing control of Repligen.
Repligen Corporation’s common stock ownership has been updated by several Eddleman-related trusts in an amended Schedule 13G.
The Roy T. Eddleman Living Trust reports beneficial ownership of 2,705,689 shares of Repligen common stock, representing 4.81% of the class. The Roy T. Eddleman Charitable Remainder Trust #1 reports beneficial ownership of 29,604 shares, representing 0.001% of the class, while Charitable Remainder Trust #2 reports no shares. Co‑trustees Geoffrey Paul, Nereyda Rubio and Anis Garci share voting and investment power over a total of 2,735,293 shares. The filing states these securities are held on a passive basis and not for the purpose of changing or influencing control of Repligen.
FMR LLC and Abigail P. Johnson report a 5.1% beneficial stake in Repligen Corp common stock. As of December 31, 2025, they report beneficial ownership of 2,891,140.17 shares, representing 5.1% of the outstanding common stock. FMR LLC has sole voting power over 2,876,401.55 shares and sole dispositive power over 2,891,140.17 shares, while Abigail P. Johnson has sole dispositive power over the same 2,891,140.17 shares with no voting power. The securities are certified as being held in the ordinary course of business and not for the purpose of changing or influencing control of Repligen. One or more other persons may have rights to dividends or sale proceeds, but no single such interest exceeds five percent of the class.
Repligen Corporation reported new equity awards to its Chief Product Officer, Douglass Brian Robb. On 12/31/2025, he received 2,288 restricted stock units, each representing one share of Repligen common stock. These restricted stock units vest in substantially equal annual installments over three years, beginning on the first anniversary of the grant date, and are settled only in shares of common stock.
On the same date, he was also granted a stock option for 2,143 shares of common stock at an exercise price of $163.86 per share, expiring on 12/31/2035. Following the restricted stock award, he directly beneficially owned 8,540 shares of common stock, and 2,143 stock options were beneficially owned directly after the option grant.
Repligen Corporation’s Chief Product Officer, Douglass Brian Robb, reported his beneficial ownership as of December 31, 2025. He directly holds 6,252 shares of Repligen common stock, which include restricted stock units granted on May 7, 2024 (4,000 units vesting in equal annual installments over five years) and on March 1, 2025 (2,252 units vesting in equal annual installments over four years).
He also holds two stock option awards, each exercisable for Repligen common stock at an exercise price of $167.72 per share and expiring on May 7, 2034: one covering 2,980 shares, with 596 shares already vested and the remainder vesting annually from May 7, 2026 through May 7, 2029, and another covering 7,020 shares, with 1,404 shares vested and the rest vesting on the same schedule. All reported holdings are listed as directly owned.